Trial Profile
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Biomarker; Therapeutic Use
- Acronyms FIRSTMAPPP
- 02 Aug 2022 Status changed from recruiting to completed.
- 25 Jan 2017 Planned End Date changed from 1 Dec 2019 to 1 Jun 2021.
- 25 Jan 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2021.